AUTHORS
Maria Carla Giarratana, MD, Lili Kotmayer, MD, PhD2, Nathan Gray, PA-C3, Michelle Boals, NP4, Alison A. Bertuch, MD, PhD5, Jeffrey Deyo, MD, PhD6, Sakshi Bami7, Marcin W Wlodarski, MD, PhD8
AFFILIATIONS
1 IRCCS, Istituto Giannina Gaslini, Genova, Liguria, Italy, St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 Baylor College of Medicine, Houston, Texas, United States
6 St. Jude Baton Rouge Affiliate Clinic, Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States
7 St. Jude Baton Rouge Affiliate Clinic, Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States
8 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
ABSTRACT
We recently described germline MDM4 loss-of-function (LOF) variants causing bone marrow failure (BMF) driven by constitutive p53 activation (Sharma 2026, PMID 41758987). In that cohort, 6 unrelated probands presented at a median age 10 years (range 4 weeks–53 years) with hematologic phenotypes from isolated neutropenia and red cell aplasia to pancytopenia and hypocellular MDS, with dysplastic hypocellular marrow in all. Its genetic counterpart, germline TP53 gain-of-function (GOF) syndrome, has been reported in 5 individuals across 3 publications (Toki 2018, PMID 30146126, n=2; Fedorova 2022, PMID 35084091, n=2; Kumar 2022, PMID 35362179, n=1). Here, we add 4 TP53-GOF syndrome cases ascertained from a single family carrying a novel TP53 variant and re-analyze all 9 individuals together to decipher recurrent patterns, comparing against MDM4 haploinsufficiency.
All 9 carry heterozygous C-terminal truncating TP53 variants clustering in exon 10 (published: p.Ser362Alafs*8 n=3, p.S362Efs*20 n=1, c.1100+1G>C n=1; ours: p.Ala355Valfs*6, NM_000546.6). Variants were de novo in 4, of unknown inheritance in 1; in our family, 2 affected first cousins inherited the variant from their mothers, who are half-sisters, who both reported microcephaly with childhood neurodevelopmental abnormalities but normal blood counts (one with remote transient anemia). All TP53 premature truncation variants identified fall within 50 nt of the terminal exon–exon junction and therefore escape nonsense-mediated decay, yielding a stable p53 protein lacking the C-terminal 26–36 residues. This domain carries the principal ubiquitination sites; its loss abolishes MDM2-mediated proteasomal turnover and negative autoregulation, resulting in a constitutively hyperactive p53.
Seven of 9 individuals (78%) presented with hematologic symptoms during infancy (median age 2 months , range birth–22 months); 5/7 were male. All phenocopied DBA syndrome: macrocytic anemia (median Hb 5g/dl, range, 3.5–6.6; median MCV 99.7 fL, range, 93–103.5), with reticulocytopenia and absent/markedly reduced marrow erythroid precursors but preserved granulopoiesis and megakaryopoiesis. No somatic alterations were identified by cytogenetics, myeloid NGS panel, and SNP array, and chromosome breakage testing was normal. Immunologic abnormalities included hypogammaglobulinemia requiring IVIG (n=2), B-cell lymphopenia (n=4), T-cell lymphopenia (n=2); only 1 had clinically significant infections. Telomere length was normal in 2/5 measured cases and low (1-10th perc.) in 3/5 cases. Neurodevelopmental manifestations were common: microcephaly in 8/9 (89%, including both carrier mothers), cognitive delay in 4/9, short stature in 3/9 and seizures in 4/9.
Corticosteroids, given in 6/7 patients yielded response in 3 (both of our patients experienced an initial response to prednisone 2 mg/kg/d; one remains responsive, the other’s anemia worsened with tapering of prednisone and remains transfusion-dependent at age 2 years). L-leucine was given in 2 and followed by transfusion independence; 1 remitted spontaneously. Of the total cohort, at last follow-up, 7/9 were transfusion-independent and 1/9 transfusion-dependent, 8/9 are alive; the only death occurred in the single patient who underwent hematopoietic stem cell transplantation (HSCT). Over 91.2 person-years of cumulative follow-up (from birth) none of the 9 patients developed a malignancy, clonal hematopoiesis, or an MDS-defining cytogenetic lesion.
In summary, while germline TP53 GOF and MDM4 LOF converge on p53 hyperactivity, their phenotypes diverge. Pure red cell aplasia occurred in 7/7 symptomatic TP53-GOF individuals versus 1/6 MDM4 probands, in whom disease presented later (median 10 years), was multilineage with dysplastic hypocellular marrow. Conversely, microcephaly was present in 8/9 TP53-GOF but 0/6 MDM4 cases. This suggests a truncated, constitutively active p53 protein generates a stronger and more erythroid-restricted p53 output than the dosage-dependent de-repression of wild-type p53 caused by MDM4 haploinsufficiency. TP53 gene should be sequenced in RP-mutation-negative DBA, particularly with microcephaly. The absence of cancer separates TP53 activation syndrome from Li-Fraumeni syndrome.
DISCLOSURES
Marcin W Wlodarski, MD, PhD: No relevant conflicts of interest to declare.